NuVasive to acquire Osiris unit

05/8/2008 | Houston Chronicle (tiered subscription model)

NuVasive will purchase Osteocol, a subsidiary of Osiris Therapeutics, in a deal that allows it to gain access to the unit's developing stem cell technology and expand into the biotech market. The acquisition, which will close in the third quarter, includes $35 million in cash and future milestone payments to Osiris worth up to $50 million.

View Full Article in:

Houston Chronicle (tiered subscription model)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC